Cargando…

Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study

Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is usually detected in a patient known to have SSc but may be diagnosed prior to SSc. We probed an insurance database to investigate documentation of ILD prior to SSc. Using Optum’s Clinformatics(®) Data Mart Database, we identified p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Assassi, Shervin, Shao, Nan, Yin, Ziwei, Volkmann, Elizabeth R., Zoz, Donald F., Leonard, Thomas B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371507/ https://www.ncbi.nlm.nih.gov/pubmed/35960051 http://dx.doi.org/10.1097/MD.0000000000029993

Ejemplares similares

Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States
por: Fan, Yanni, et al.
Publicado: (2020)

Predictors of progression in systemic sclerosis patients with interstitial lung disease
por: Distler, Oliver, et al.
Publicado: (2020)

Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease
por: Assassi, Shervin, et al.
Publicado: (2022)

The Role of Type 1 Interferon in Systemic Sclerosis
por: Wu, Minghua, et al.
Publicado: (2013)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease
por: Volkmann, Elizabeth R., et al.
Publicado: (2016)

Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention
por: Fischer, Aryeh, et al.
Publicado: (2019)

Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy
por: Volkmann, Elizabeth R., et al.
Publicado: (2023)

Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort
por: Assassi, Shervin, et al.
Publicado: (2010)

Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need
por: Herrick, Ariane L., et al.
Publicado: (2022)

Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study
por: Mihai, Carina, et al.
Publicado: (2020)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
por: Bergamasco, Aurore, et al.
Publicado: (2019)

Racial Disparities in Systemic Sclerosis: Short‐ and Long‐Term Outcomes Among African American Participants of SLS I and II
por: Volkmann, Elizabeth R., et al.
Publicado: (2020)

The Effect of Anti‐Scl‐70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis
por: Jandali, Bochra, et al.
Publicado: (2022)

Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis
por: Yamakawa, Hideaki, et al.
Publicado: (2016)

Osteopontin in Systemic Sclerosis and its Role in Dermal Fibrosis
por: Wu, Minghua, et al.
Publicado: (2012)

Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial
por: Assassi, Shervin, et al.
Publicado: (2022)

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial
por: Volkmann, Elizabeth R, et al.
Publicado: (2022)

Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
por: Rahaghi, Franck F., et al.
Publicado: (2023)

Extensive and Persistent Extravascular Dermal Fibrin Deposition Characterizes Systemic Sclerosis
por: Browning, Jeffrey L., et al.
Publicado: (2023)

Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit
por: Kakkar, Vishal, et al.
Publicado: (2022)

Predictors of Fatigue Severity in Early Systemic Sclerosis: A Prospective Longitudinal Study of the GENISOS Cohort
por: Assassi, Shervin, et al.
Publicado: (2011)

Living with Systemic Sclerosis: A Patient and Physician Perspective
por: Young, Arissa, et al.
Publicado: (2023)

Interstitial lung disease pathology in systemic sclerosis
por: Konopka, Kristine E., et al.
Publicado: (2021)

Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States
por: Bernstein, Elana J., et al.
Publicado: (2022)

Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study
por: Hamberg, Viggo, et al.
Publicado: (2023)

Transcriptional insights into pathogenesis of cutaneous systemic sclerosis using pathway driven meta-analysis assisted by machine learning methods
por: Xu, Xiao, et al.
Publicado: (2020)

Predicting the Progression of Very Early Systemic Sclerosis: Current Insights
por: Bellocchi, Chiara, et al.
Publicado: (2022)

Micronutrient Deficiencies in Systemic Sclerosis: A Scoping Review
por: Nguyen, Audrey D, et al.
Publicado: (2022)

Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations
por: Gourh, Pravitt, et al.
Publicado: (2009)

Right Bundle Branch Block: A Predictor of Mortality in Early Systemic Sclerosis
por: Draeger, Hilda T., et al.
Publicado: (2013)

Circulating Biomarkers of Interstitial Lung Disease in Systemic Sclerosis
por: Lota, Harpreet K., et al.
Publicado: (2012)

Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis
por: Yasuoka, Hidekata
Publicado: (2016)

Pathogenesis of systemic sclerosis associated interstitial lung disease
por: Nihtyanova, Svetlana I, et al.
Publicado: (2020)

Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease
por: Khanna, Dinesh, et al.
Publicado: (2020)

Augmented concentrations of CX(3)CL1 are associated with interstitial lung disease in systemic sclerosis
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2018)

Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study
por: Li, Qiang, et al.
Publicado: (2020)

Multiple Manifestations of Systemic Sclerosis Affect Walk Distance
por: Andréasson, Kristofer, et al.
Publicado: (2021)

Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis
por: Choi, May Y., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jcfolgrf4eoesillornid6m2nh